These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1274 related items for PubMed ID: 16322337

  • 1. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, Angelucci A, Dolo V, Vicentini C, Bologna M.
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [Abstract] [Full Text] [Related]

  • 2. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
    She QB, Solit D, Basso A, Moasser MM.
    Clin Cancer Res; 2003 Oct 01; 9(12):4340-6. PubMed ID: 14555504
    [Abstract] [Full Text] [Related]

  • 3. Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.
    Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C, Bologna M.
    Prostate; 2008 Jun 15; 68(9):965-74. PubMed ID: 18361408
    [Abstract] [Full Text] [Related]

  • 4. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B, Zhou C.
    Adv Med Sci; 2011 Jun 15; 56(2):275-84. PubMed ID: 22037177
    [Abstract] [Full Text] [Related]

  • 5. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S, Chrétien AS, Ramacci C, Rouyer M, Becuwe P, Merlin JL.
    Oncol Rep; 2009 Mar 15; 21(3):731-5. PubMed ID: 19212633
    [Abstract] [Full Text] [Related]

  • 6. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
    Wu Z, Gioeli D, Conaway M, Weber MJ, Theodorescu D.
    Prostate; 2008 Jun 15; 68(9):935-44. PubMed ID: 18386291
    [Abstract] [Full Text] [Related]

  • 7. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
    Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S.
    J Cell Physiol; 2006 May 15; 207(2):420-7. PubMed ID: 16419029
    [Abstract] [Full Text] [Related]

  • 8. Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer.
    Li P, Zhang Q, Torossian A, Li ZB, Xu WC, Lu B, Fu S.
    Int J Radiat Oncol Biol Phys; 2012 Jul 01; 83(3):e391-7. PubMed ID: 22414288
    [Abstract] [Full Text] [Related]

  • 9. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
    Noro R, Gemma A, Kosaihira S, Kokubo Y, Chen M, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Kudoh S.
    BMC Cancer; 2006 Dec 06; 6():277. PubMed ID: 17150102
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
    Festuccia C, Angelucci A, Gravina GL, Biordi L, Millimaggi D, Muzi P, Vicentini C, Bologna M.
    Thromb Haemost; 2005 May 06; 93(5):964-75. PubMed ID: 15886816
    [Abstract] [Full Text] [Related]

  • 14. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).
    Kokubo Y, Gemma A, Noro R, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Shibuya M, Kudoh S.
    Br J Cancer; 2005 May 09; 92(9):1711-9. PubMed ID: 15870831
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL, Kelly JD, Neal DE, King SM, Davies BR.
    Clin Cancer Res; 2004 Jul 15; 10(14):4874-84. PubMed ID: 15269164
    [Abstract] [Full Text] [Related]

  • 16. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll JL, Hurbin A.
    Int J Cancer; 2014 Jun 01; 134(11):2560-71. PubMed ID: 24374738
    [Abstract] [Full Text] [Related]

  • 17. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
    Xing WJ, Zou Y, Han QL, Dong YC, Deng ZL, Lv XH, Jiang T, Ren H.
    Clin Exp Pharmacol Physiol; 2013 Jan 01; 40(1):13-21. PubMed ID: 23110505
    [Abstract] [Full Text] [Related]

  • 18. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.
    Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CP, McConkey DJ.
    Cancer Res; 2007 Feb 15; 67(4):1430-5. PubMed ID: 17308080
    [Abstract] [Full Text] [Related]

  • 19. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.
    Adv Enzyme Regul; 2006 Feb 15; 46():249-79. PubMed ID: 16854453
    [Abstract] [Full Text] [Related]

  • 20. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B, Chang CM, Yuan M, McKenna WG, Shu HK.
    Cancer Res; 2003 Nov 01; 63(21):7443-50. PubMed ID: 14612544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.